TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 02/01/24

2024-02-01 02:26:23 ET Takeda Pharmaceutical ( NYSE: TAK ) said that Costa Saroukos, CFO, has decided to leave Takeda to return to his home-country of Australia to be closer to family. ... Read the full article on Seeking Alpha For further details ...

Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos will step down as CFO, effective April 1, 2024 and will remain with the company as a board directo...

2024-02-01 01:21:16 ET More on Takeda Pharmaceutical EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze Takeda wins EU approval for Hyqvia CIDP indication Seeking Alpha’s Quant Rating on Takeda Pharmaceutical Historical earnings data for Ta...

Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTP Strong Commercial Execution Maximizing Value of Existing Portfolio: ENTYVIO ® Pen Launched...

2024-01-29 17:25:44 ET More on Halozyme Therapeutics, Takeda Pharmaceutical, etc. Halozyme Therapeutics: A Reasonable Value In An Overvalued Market Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings...

New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin (IG) Portfolio to Meet the Needs of People Living with CIDP Approval Supported by Phase 3 ADVANCE-CIDP Open-label Study Data Demonstrating Safety and Efficacy as an Intravenous Ther...

2024-01-29 06:06:17 ET The European Commission has approved Takeda's ( NYSE: TAK ) Hyqvia as maintenance therapy in patients of all ages with a neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP).... Read the full article on Seeking Alpha ...

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients an up to Once-Monthly Treatment Option At-Home or In-Office Administration Provides CIDP Patients with a Personalized Treatmen...

2024-01-26 12:47:12 ET Summary Today, we take another look at Halozyme Therapeutics, Inc., which enhances drug delivery through its ENHANZE platform, earning royalties and milestone payouts from major drugmakers. Management has plans in place to more than double royalty revenues b...

2024-01-25 17:09:29 ET More on Cognizant Technology Cognizant: 2024 Is Unlikely To Be A Repeat Of 2023 Cognizant Can Go Up And Down, But I Say 'Hold' Cognizant: I Stay Cautious For Now Read the full article on Seeking Alpha For further details see: ...